Adial to file fast track application for ad04 with the fda

Charlottesville, va., feb. 23, 2021 (globe newswire) -- adial pharmaceuticals, inc. (nasdaq: adil; adilw) (“adial” or the “company”), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that it will be filing an application for “fast track” with the u.s. food and drug administration (fda) for its lead drug candidate, ad04, which is a therapeutic agent for the treatment of alcohol use disorder (aud) in persons with certain target genotypes.
ADIL Ratings Summary
ADIL Quant Ranking